<html><!-- #BeginTemplate "/Templates/annrept.dwt" -->
<head>
<!-- #BeginEditable "doctitle" --> 
<title>Unit on Genetics and Endocrinology</title>
<!-- #EndEditable --> 
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<style type="text/css">
<!--
.mem_title {  font-family: Arial, Helvetica, sans-serif; font-size: 12px; font-style: italic}
.detail {  font-family: "Times New Roman", Times, serif; font-size: 14px}
.pub_title {  font-family: Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold}
.pub_text {  font-family: "Times New Roman", Times, serif; font-size: 14px}
.head_name {  font-family: Arial, Helvetica, sans-serif; font-size: 12px; font-weight: bold}
.mem_name {  font-family: Arial, Helvetica, sans-serif; font-size: 12px}
.page_title {  font-family: Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold}
.figure {  font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal}
.head_title {  font-family: Arial, Helvetica, sans-serif; font-size: 12px; font-style: italic; font-weight: bold}
.subscript {  font-family: "Times New Roman", Times, serif; font-size: 9px; vertical-align: sub}
.superscript {  font-family: "Times New Roman", Times, serif; font-size: 9px; vertical-align: super}
.navigation {  font-family: Arial, Helvetica, sans-serif; font-size: 12px}
-->
</style>
</head>

<body bgcolor="#FFFFFF" text="#000000">
<div align="center"> </div>
<table width="580" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td colspan="4" height="40" class="navigation"> 
      <div align="center"><!-- #BeginEditable "navigation" class="navigation"  --><a href="sep.html">SEP</a> 
  | <a href="sgm.html">SGM </a>| <a href="ugd.html">UGD </a>| <a href="uge.html">UGE</a> 
  | <a href="ugen.html">UGEN</a> | <a href="ugo.html">UGO</a> | <a href="uts.html">UTS</a> 
  | <a href="deb.html">Main Page</a><!-- #EndEditable --></div>
    </td>
  </tr>
  <tr> 
    <td colspan="4" height="19" class="page_title">&nbsp;</td>
  </tr>
  <tr> 
    <td colspan="4" height="19" class="page_title"> 
      <div align="center"><!-- #BeginEditable "title" -->ENDOCRINE GENETICS<!-- #EndEditable --></div>
    </td>
  </tr>
  <tr> 
    <td width="44%" valign="top">&nbsp;</td>
    <td width="19%">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
  </tr>
  <tr> 
    <td colspan="2" valign="top" class="mem_name"><!-- #BeginEditable "lab_members" -->
      <p><span class="head_name"><a href="mailto:cs143u@nih.gov">Constantine Stratakis, 
        M.D.</a>, D.Sc.</span>, <span class="head_title">Principal Investigator</span><br>
        <a href="mailto:lk67n@nih.gov">Lawrence S. Kirschner, M.D., Ph.D.</a>, 
        <span class="mem_title">Senior Staff Fellow</span><br>
        <a href="mailto:tb258c@nih.gov">Thalia Bei, Ph.D.</a>, <span class="mem_title">Guest 
        Researcher</span><br>
        <a href="mailto:ib56b@nih.gov">Isabelle Bourdeau, M.D.</a>, <span class="mem_title">Guest 
        Researcher</span><br>
        <a href="mailto:lm246o@nih.gov">Ludmila Matyakhina, Ph.D.</a>, <span class="mem_title">Visiting 
        Fellow</span><br>
        <a href="mailto:fs62s@nih.gov">Fabiano Sandrini, M.D.</a>, <span class="mem_title">Visiting 
        Fellow</span><br>
        Constantine Farmakidis, B.S., <span class="mem_title">Predoctoral Fellow</span><br>
        <a href="mailto:lg172z@nih.gov">Laura Gosselink, B.A.</a>,<span class="mem_title"> 
        Predoctoral Fellow</span><br>
        <a href="mailto:sl264t@nih.gov">Sara M. Lenherr, B.S.</a>, <span class="mem_title">Predoctoral 
        Fellow</span><br>
        <a href="mailto:ar232f@nih.gov">Audrey Robinson-White, Ph.D.</a>, <span class="mem_title">Volunteer</span></p>
      <p><a href="http://dir2.nichd.nih.gov/nichd/ugen/ugenindex.htm">For More 
        Information</a></p>
      <!-- #EndEditable --> 
    </td>
    <td width="4%"> 
      <div align="right"></div>
    </td>
    <td width="33%" valign="top"> 
      <div align="center"><!-- #BeginEditable "head_pic" --><img src="images/STRATAKI.jpg" width="153" height="209" alt="Constantine Stratakis"><!-- #EndEditable --></div>
    </td>
  </tr>
  <tr> 
    <td colspan="4">&nbsp;</td>
  </tr>
  <tr> 
    <td colspan="4" valign="top" class="detail"><!-- #BeginEditable "detail" --> 
      <p>The goal of our work is to understand the genetic and molecular mechanisms 
        leading to disorders that affect the adrenal cortex, with emphasis on 
        disorders that are developmental, hereditary, and associated with adrenal 
        hypoplasia or hyperplasia, multiple tumors, and abnormalities in other 
        endocrine glands (i.e., the pituitary gland). In this context, our laboratory 
        has studied congenital adrenal hypoplasia caused by Allgrove syndrome 
        (or triple A syndrome) and multiple endocrine deficiencies (APECED syndrome), 
        familial hyperaldosteronism, adrenocortical and thyroid cancer, pituitary 
        tumors and multiple endocrine neoplasia syndromes (MEN 1, Cowden disease) 
        affecting the pituitary, thyroid, and adrenal glands, and Carney complex, 
        an autosomal dominant disease that affects the adrenal cortex. Carney 
        complex is the only inherited form of adrenal gland-dependent Cushing&#146;s 
        syndrome; it is also a mutliple endocrine neoplasia affecting the pituitary 
        and thyroid glands and the gonads and is associated with a variety of 
        other tumors, including myxomas (heart and other myxomas) and schwannomas 
        (it is one of three conditions associated with inherited schwannomas; 
        the other two are neurofibromatosis and isolated schwannomatosis), and 
        skin pigmentation defects (lentigines, caf&eacute;-au-lait spots, and 
        nevi). Recently, our laboratory identified the regulatory subunit type 
        1-_ (Ri_) __of protein kinase A (PKA), which is coded by the PRKAR1A gene, 
        the gene responsible for almost half the cases of Carney complex. Since 
        then, our laboratory has largely focused on PKA-stimulated signaling pathways, 
        PKA effects on tumor suppression and/or development, the cell cycle and 
        chromosomal stability, and PKA-dependent hormonal interactions. <br>
        <b><br>
        Carney Complex Genetics</b><br>
        <i>Kirschner, Bei, Bourdeau, Matyakhina, Sandrini, Stratakis in collaboration 
        with J.A. Carney (Mayo Clinic)</i><br>
        Families with Carney complex (CNC) and related syndromes from a number 
        of collaborating institutions worldwide have been accessed. Genetic linkage 
        analysis located two loci harboring genes for CNC on chromosomes 2 (2p16) 
        and 17 (17q22-24) while a possible third locus for this genetically heterogeneous 
        condition is currently under investigation. With the application of state-of-the-art 
        molecular cytogenetic techniques, the participation of the two genomic 
        loci on chromosomes 2 and 17 in the expression of the disease is undergoing 
        study. A comprehensive genetic and physical map of the 2p16 chromosomal 
        region was constructed for the cloning of the CNC-associated sequences 
        from this region. Studies in cultured primary tumor cell lines (established 
        from our patients) identified a region of genomic instability in the center 
        of the map. Tumor studies (Figure 1) led to the identification of the 
        PRKAR1A gene on 17q22-24 as the gene responsible for CNC in approximately 
        40 percent of cases of the disease. PRKAR1A was identified as a novel 
        tumor suppressor gene in CNC-associated tumors; it is also the main regulatory 
        subunit of protein kinase A (PKA), a central signaling pathway for many 
        cellular functions and hormonal responses. With more patients with CNC 
        now participating in genotype-phenotype correlation studies, the studies 
        are expected to shed light on the complex biochemical and molecular pathways 
        regulated by PRKAR1A and PKA.</p>
      <p align="center"><img src="images/2_DEB_S2.jpg" width="400" height="300" alt="Figure 3"></p>
      <p align="center" class="figure">Figure 3 </p>
      <p align="left" class="figure">Mapping of the PRKAR1A gene on chromosome 
        17 and identification of genetic markers of the PRKAR1A locus that were 
        used for genetic studies in CNC families (left panel). A probe containing 
        the PRKAR1A gene from a chromosome 17 human genome library was then used 
        in an ovarian tumor cell line from a patient with CNC in a fluorescent 
        in situ hybridization experiment (right panel); the cells demonstrate 
        allelic loss of the PRKAR1A-containing probe (one copy per cell instead 
        of two), suggesting that PRKAR1A is a tumor suppressor gene.</p>
      <p><b>PRKAR1A Effects on Protein Kinase A Activity and Endocrine Tumor Development</b><br>
        <i>Kirschner, Matyakhina, Sandrini, Lenherr, Gosselink, Robinson-White, 
        Stratakis in collaboration with Y. Cho-Chung (NCI) </i><br>
        The functional consequences of PRKAR1A mutations are being investigated 
        in cell lines established from CNC patients and their tumors. Both cAMP 
        and PKA activity are measured in the cell lines, along with the expression 
        of the other subunits of the PKA tetramer. We have established stable 
        transfectants of antisense PRKAR1A constructs in mouse endocrine and other 
        commercially available cell lines and have studied the cell lines for 
        the effects of PRKAR1A silencing on cell growth, differentiation, and 
        proliferation. It is hypothesized that the tumorigenicity of PRKAR1A-inactivating 
        mutations relies on the switch from type-I PKA (based almost exclusively 
        on endocrine cells on PRKAR1A) to type-II PKA activity; cell lines with 
        an antisense PRKAR1A construct are believed to be a representative model 
        of the in vivo situation in CNC patients. In addition, we are looking 
        for mutations of the PRKAR1A gene that would further establish its role 
        as a general tumor suppressor in sporadic endocrine and nonendocrine tumors 
        (thyroid adenomas and carcinomas, adrenocortical adenomas and carcinomas, 
        ovarian carcinomas, melanomas and benign and malignant pigmented lesions, 
        and heart myxomas); a variety of investigators within the NIH and around 
        the world provide specimens on a collaborative basis.<br>
        <b><br>
        PRKAR1A Animal Models </b><br>
        <i>Kirschner, Gosselink, Lenherr, Stratakis in collaboration with H. Westphal 
        (LMGD, NICHD) </i><br>
        Given that the PRKAR1A-knockout (KO) (-/-) mouse (created several years 
        ago by S. McKnight of the University of Washington, Seattle) dies on day 
        nine of embryonic development of heart and central nervous system abnormalities 
        and PRKAR1A&#146;s involvement in CNC, our laboratory became interested 
        in developing alternative animal models that would address the complex 
        in vivo effects of PRKAR1A inactivation. The several animal models under 
        development in our laboratory fall into two categories: conditional PRKAR1A 
        KOs in endocrine tissues (adrenal cortex, anterior lobe of the pituitary 
        and the thyroid gland) and (2) transgenic antisense PRKAR1A expression.<br>
        <b><br>
        PRKAR1A, the Cell Cycle, Chromosomal Stability, and Other Signaling Pathways</b><br>
        <i>Matyakhina, Robinson-White, Stratakis in collaboration with V. Papadopoulos 
        (Georgetown University, Washington DC)</i><br>
        Genes implicated in cyclic nucleotide-dependent signaling have long been 
        considered likely candidates for endocrine tumorigenesis. Somatic activating 
        mutations in a number of G-protein coupled receptors (GPCRs) and the gene 
        coding for a subunit of the stimulatory G protein (GNAS1) lead to increased 
        cAMP production and are responsible for a number of endocrine tumors of 
        various types. To date, however, there is no convincing evidence that 
        GNAS1 or GPCR activation in the absence of additional genetic abnormalities 
        is involved in cancer. Individuals with McCune-Albright syndrome (MAS, 
        a disease similar to CNC) who bear somatic GNAS1 mutations in their endocrine 
        glands may be predisposed to some cancers. However, activation of additional 
        pathways and/or other changes appear to be required for the in vitro transformation 
        of 3T3 or FRTL5 cells by constitutively active GPCR transgenes or in other 
        settings of increased cAMP signaling that lead to malignant transformation. 
        Thus, other genes that regulate PKA function and increase cAMP-dependent 
        proliferation and related signals may be altered in the process of endocrine 
        tumorigenesis initiated by a mutant PRKAR1A, a gene with important functions 
        in the cell cycle as well as in chromosomal stability. Our work aims to 
        identify the interactions of PRKAR1A by studying mitogenic and other growth 
        signaling pathways in cell lines that express the antisense PRKAR1A contructs 
        referred to above. In addition, chromosomal stability in both human and 
        mouse cell lines in which PRKAR1A has been inactivated is under investigation 
        with the techniques of classic and molecular cytogenetics, including fluorescent 
        in situ hybridization (FISH), spectral karyotyping (SKY), and comparative 
        genomic hybridization (CGH). Finally, more recently, we are investigating 
        proteins that are directly bound to PRKAR1A (RI_) and regulate its function, 
        including a novel protein, PAP7 that a collaborating laboratory identified. 
        Compartmentalization of PKA function is supposed to be mediated by anchoring 
        proteins; almost all the PKA anchoring proteins known to date, however, 
        are bound to type II-PKA. PAP7 may be the first PKA type-I-specific anchoring 
        protein.<br>
        <b><br>
        Genetic Investigations on Other Adrenocortical Diseases and Tumors</b><br>
        <i>Bourdeau, Sandrini, Farmakidis, Stratakis in collaboration with S. 
        Libutti (NCI), W.Y. Chan (NICHD), J.A. Carney (Mayo Clinic), M Stowasser 
        and D Torpy (University of Queensland, Australia), A. Lacroix (University 
        of Montreal, Canada), and J. Bertherat (Hospital Cochin, France)</i><br>
        Our work aims at using general and pathway-specific microarrays on a variety 
        of adrenocortical tumors to identify genes with important functions in 
        adrenal oncogenetics; examining specific candidate genes (such as TP53 
        and other tumor suppressors and oncogenes) for their roles in adrenocortical 
        tumors and development; and identifying by positional cloning additional 
        genes with a role in inherited adrenocortical diseases. Our laboratory 
        engages in collaborations for a large part of its work, as is evident 
        from the number of collaborating investigators and institutions. As part 
        of this work, we and our collaborators have recently completed the following: 
        identification of a novel TP53 mutation in a cohort of adrenocortical 
        tumors from southern Brazil with important implications for p53&#146;s 
        function in adrenocortical tumor suppression; development of a genomewide 
        screen for the identification of gene(s) responsible for inherited adrenocortical 
        aldosteronomas (familial hyperaldosteronism type II - FH-II) and that 
        identified a locus for FH-II on chromosome 7 (7p22); ongoing development 
        of a genomewide screen for the identification of a syndrome composed of 
        familial paragangliomas and adrenal, gastric stromal. and pulmonary tumors; 
        and the identification of new mutations in the APECED and Allgrove syndrome 
        genes leading to congenital adrenal hypoplasia.<br>
        <b><br>
        Genetic Investigations on Other Endocrine Neoplasias and Related Syndromes</b><br>
        <i>Bourdeau, Sandrini, Stratakis</i><br>
        Additional work in our laboratory is exploring the genetics of CNC- and 
        adrenal-related endocrine tumors, including childhood adrenocortical cancer 
        and thyroid and pituitary tumors. As part of this work, we described a 
        novel form of acromegaloid syndrome in which the responsible genetic defect 
        was associated with a chromosome 11 abnormality (see figure). Finally, 
        we are identifying the genetic defects in patients with CNC-related syndromes 
        (the lentigenoses, i.e., Peutz-Jeghers syndrome and others) largely in 
        collaboration with several other investigators at the NIH and elsewhere.<br>
      </p>
      <p align="center"><img src="images/2_DEB_ST.jpg" width="475" height="204" alt="Figure 4"></p>
      <p>&nbsp;</p>
      <p class="figure" align="center">Figure 4</p>
      <p class="figure">A) G-banding high resolution karyotype of a patient with 
        pseudoacromegaly; the arrows point to a newly described chromosome 11 
        abnormality [inv(11)(p15.3;q23.3)], which is undetectable without proper 
        analysis of band density. B) Fluorescent in situ hybridization on cultured 
        lymphocytes from the proband with two probes that hybridize to the 11p 
        telomere (11pter) and to the MLL gene on 11q23, respectively, showing 
        that, on one chromosome 11, the two probes were positioned proximal to 
        each other (arrow), whereas they hybridized to their expected positions 
        on the other chromosome.</p>
      <p><b>Clinical Investigations in the Diagnosis and Treatment of Adrenal 
        and Pituitary Tumors </b><br>
        <i>Kirschner, Stratakis, Keil</i><br>
        Patients with adrenal tumors and other types of Cushing&#146;s syndrome 
        (and occasionally other pituitary tumors) come to the NIH Clinical Center 
        for diagnosis and treatment. Ongoing investigations include the prevalence 
        of ectopic hormone receptor expression in adrenal adenomas and massive 
        macronodular adrenocortical disease; the diagnostic use of high- sensitivity 
        magnetic resonance imaging for the earlier detection of pituitary tumors; 
        the diagnosis, management, and postoperative care of children with Cushing&#146;s 
        disease and other pituitary tumors.</p>
      <p>&nbsp;</p>
      <!-- #EndEditable --></td>
  </tr>
  <tr valign="top"> 
    <td colspan="4">&nbsp;</td>
  </tr>
  <tr valign="top"> 
    <td colspan="4" class="pub_text"> <!-- #BeginEditable "publications" -->
      <p class="pub_title">PUBLICATIONS</p>
      <!-- #EndEditable --><!-- #BeginEditable "pub_text" class="pub_text" --> 
      <ol>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11181578&dopt=Abstract">Balemans 
          W, Ebeling M, Patel N, Hul EV, Olson P, Dioszegl, Lacza C, Wuyts W, 
          Van den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, 
          Tacconi P, Dikkers FG, _Stratakis CA, Lindpaintner K, Vickery B, Foernzler 
          D, Van Hul W</a>. Increased bone density in sclerosteosis is due to 
          the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10:537-543.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10874301&dopt=Abstract">Boardman 
          LA, Couch FJ, Burgart LJ, Schwartz D, Berry R, McDonnell SK, Schaid 
          DJ, Hartmann LC, Schroeder JJ, Stratakis CA, Thibodeau SN</a>. Genetic 
          heterogeneity in Peutz-Jeghers syndrome. Hum Mutat 2000;16:23-30.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11176065&dopt=Abstract">Carney 
          JA, Boccon-Gibod L, Jarka D, Tanaka Y, Swee RG, Unni KK, Stratakis CA</a>. 
          Osteochondromyxoma of bone: a congenital tumor associated with lentigines 
          and other unusual disorders. Am J Surg Pathol 2001;25:164-176.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10966714&dopt=Abstract">Doppman 
          JL, Chrousos GP, Papanicolaou DA, Stratakis CA, Bartlet DL, Nieman LK</a>. 
          Adrenococrticotropin (ACTH)-independent macronodular adrenal hyperplasia; 
          an uncommon cause of primary adrenal hypercortisolism. Radiology 2000;216:797-802.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11174387&dopt=Abstract">Egan 
          CA, Stratakis CA, Turner ML</a>. Multiple lentigines associated with 
          cutaneous myxomas. Am J Acad Dermatol 2001;44:282-284.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11502819&dopt=Abstract">Glasow 
          A, Horn L-C, Taymans SE, Stratakis CA, Kelly PA, Kohler U, Gillespie 
          J, Vonderhaar BK, Bornstein SR</a>. Mutational analysis of the prolactin 
          receptor (PRLR) gene in human breast tumors with differential PRLR protein 
          expression. J Clin Encocrinol Metab 2001;86:3826-3832.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10973256&dopt=Abstract">Kirschner 
          LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, 
          Stratakis CA</a>. Mutations of the gene encoding the protein kinase 
          A type I-alpha regulatory subunit in patients with the Carney complex. 
          Nat Genet 2000;26:89-92.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11115848&dopt=Abstract">Kirschner 
          LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis CA</a>. Genetic 
          heterogeneity and spectrum of mutations of the PRKAR1A gene in patients 
          with Carney complex. Hum Mol Genet 2000;9:3037-3046. <br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10772958&dopt=Abstract">Kirschner 
          LS, Stratakis CA</a>. Gene structure of the human ubiquitin fusion gene 
          Uba80 (RPS27a) and one of its pseudogenes. Biochem Biophys Res Commun 
          2000;270:1106-1110.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11134164&dopt=Abstract">Kirschner 
          LS, Stratakis CA</a>. Isolated familial somatotropinomas: does the disease 
          map to 11q13 or to 2p16? (Letter) J Clin Endocrinol Metab 2000;85:4920-4924.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11073536&dopt=Abstract">Lafferty 
          AR, Torpy DJ, Stowasser M, Taymans SE, Lin JP, Huggard P, Gordon RD, 
          Stratakis CA</a>. A novel genetic locus for low renin hypertension: 
          familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med 
          Genet 2000;37:831-835.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11443851&dopt=Abstract">Marsh 
          DJ, Stratakis CA</a>. Hamartoma and lentiginosis syndromes: clinical 
          and molecular aspects. In: Dahia PLM, Eng, C, eds. Genetic disorders 
          of endocrine neoplasia. Front Horm Res 2001;28:167-213.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11102943&dopt=Abstract">Ng 
          D, Stratakis CA</a>. Premature adrenal cortical dysfunction in mandibuloacral 
          dysplasia, a progeroid-like syndrome. Am J Med Genet 2000;95:293-295.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11061550&dopt=Abstract">Pack 
          S, Kirshner LS, Pak E, Carney JA, Zhuang Z, Stratakis CA</a>. Pituitary 
          tumors in patients with the complex of spotty skin pigmentation, myxomas, 
          endocrine overactivity and schwannomas (Carney complex): evidence for 
          progression from somatomammotroph hyperplasia to adenoma. J Clin Encocrinol 
          Metab 2000;85:3860-3865.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10776991&dopt=Abstract">Raff 
          SB, Carney JA, Krugman D, Doppman JL, Stratakis CA</a>. Prolactin secretion 
          abnormalities in patients with the &quot;syndrome of spotty skin pigmentation, 
          myxomas, endocrine overactivity and schwannomas.&quot; J Pediatr Endocrinol 
          Metab 2000;13:373-379.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11481490&dopt=Abstract">Ribeiro 
          RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty 
          AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stratakis CA, 
          Sandrini R</a>. An inherited p53 mutation that contributes in a tissue-specific 
          manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 
          2001;98:9330-9335.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11701718&dopt=Abstract">Sandrini 
          F, Farmakidis C, Kirschner LS, Wu S-M, Tullio-Pelet A, Lyonnet S, Metzger 
          DL, Bourdony CJ, Tiosano D, Chan WY, Stratakis CA</a>. Spectrum of mutations 
          of the AAAS Gene in Allgrove Syndrome: lack of mutations in six kindreds 
          with isolated resistance to corticotropin. J Clin Endocrinol Metab 2001;86:5433-5437.<br>
        </li>
        <li>Sprunger LK, Meisler MH, Stratakis CA. Recombination between the sodium 
          channel SCN8A and the Allgrove syndrome gene in a Puerto Rican kindred. 
          J Endocr Genet 2000;1:165-169.<br>
        </li>
        <li> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11407658&dopt=Abstract">Stratakis 
          CA</a>. Clinical genetics of multiple endocrine neoplasias, Carney complex 
          and related syndromes. J Endocr Invest 2001;24:370-383. <br>
        </li>
        <li>Stratakis CA. Cushing syndrome and Addison disease. In: Hughes IA, 
          Clark AJL, eds. Endocrine development: adrenal diseases in childhood, 
          clinical and molecular aspects. Basel: Karger AG, 2000;150-173.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11353891&dopt=Abstract">Stratakis 
          CA</a>. Genetics of adrenocortical tumors: Carney complex. Ann Endocrinol 
          (Paris) 2001;62:180-184.<br>
        </li>
        <li> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11595829&dopt=Abstract">Stratakis 
          CA</a>. Genetics of Peutz-Jeghers syndrome, Carney complex and other 
          familial lentiginoses. Horm Res 2000;54:334-343.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10803862&dopt=Abstract">Stratakis 
          CA, Ball DW</a>. Multiple endocrine neoplasia and related syndromes. 
          J Pediatr Endocrinol Metab 2000;13:457-465.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11549623&dopt=Abstract">Stratakis 
          CA, Kirschner LS, Carney JA</a>. Clinical and molecular features of 
          the Carney complex: diagnostic criteria and recommendations for patient 
          evaluation. J Clin Endocrinol Metab 2001;86:4041-4046.<br>
        </li>
        <li> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10999840&dopt=Abstract">Stratakis 
          CA, Lafferty A, Taymans SE, Gafni RI, Meck JM, Blancato J</a>. Anisomastia 
          associated with interstitial duplication of chromosome 16, mental retardation, 
          obesity, dysmorphic facies, and digital anomalies: molecular mapping 
          of a new syndrome by fluorescent in situ hybridization and microsatellites 
          to 16q13 (D16S419-D16S503). J Clin Endocrinol Metab 2000;85:3396-3401. 
          <br>
        </li>
        <li>Stratakis CA, Papageorgiou T, Premkumar N, Kirschner LS, Taymans SE, 
          Pack S, Zhuang Z, Oelkers WH, Carney JA. Ovarian lesions in Carney complex: 
          clinical genetics studies and possible predisposition to malignancy. 
          J Clin Encocrinol Metab 2000;85:4359-4366 [editorial in J Clin Endocrinol 
          Metab 2000;85:4010-4012].<br>
        </li>
        <li>Stratakis CA, Russovici D, Kulin HE, Finkelstein JW. ACTH and cortisol 
          responses to L-DOPA and insulin-induced hypoglycemia in children with 
          short stature. J Pediatr Endocrinol Metab 2000;13:1095-1100.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11134142&dopt=Abstract">Stratakis 
          CA, Schussheim DH, Freedman SM, Keil MF, Pack SF, Agarwal SK, Skarulis 
          MC, Weil RJ, Lubensky LA, Zhuang Z, Oldfield EH, Marx SJ</a>. Pituitary 
          macroadenoma in a 5-year-old: an early expression of Multiple Endocrine 
          Neoplasia type 1. J Clin Encocrinol Metab 2000;85:4776-4780.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10978367&dopt=Abstract">Stratakis 
          CA, Taymans SE, Daruwala R, Song J, Levine M</a>. Mapping of the human 
          genes (SLC23A2 and SLC23A1) coding for vitamin C transporters 1 and 
          2 (SVCT1 and SVCT2) to 5q23 and 20p12, respectively. J Med Genet 2000;37:E20-E23.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11288708&dopt=Abstract">Stratakis 
          CA, Taymans SE, Schteingart D, Haddad BR</a>. Segmental uniparental 
          isodisomy (UPD) for 2p16 without clinical symptoms: implications for 
          UPD and other genetic studies of chromosome 2 [Brief Report]. J Med 
          Genet 2001;38:106-109.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11403045&dopt=Abstract">Stratakis 
          CA, Turner ML, Lafferty A, Toro JR, Hill S, Meck JM, Blancato J</a>. 
          A syndrome of overgrowth and acromegaloidism with normal growth hormone 
          secretion is associated with chromosome 11 pericentric inversion [Brief 
          Report]. J Med Genet 2001;38:338-343.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11004715&dopt=Abstract">Torpy 
          DJ, Stratakis CA, Chrousos GP</a>. Familial hyperaldosteronism. Braz 
          J Med Biol Res 2000;33:1149-1155.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11446421&dopt=Abstract">Tsilou 
          E, Stratakis CA, Rubin CA, Hay BN, Patronas N, Kaiser-Kupfer MI</a>. 
          Ophthalmic manifestations of Allgrove syndrome: report of a case. Clin 
          Dysmorphol 2001;10:231-233.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10701527&dopt=Abstract">Watson 
          JC, Stratakis CA, Bryant-Greenwood PK, Koch CA, Kirschner LS, Ngyen 
          T, Carney JA, Oldfield EH</a>. Neurosurgical implications of Carney 
          complex. J Neurosurg 2000;92:413-418.<br>
        </li>
        <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11288714&dopt=Abstract">Zouboulis 
          CC, Stratakis CA, Gollnick HP, Orfanos CE</a>. Keratosis pilaris/ulerythema 
          ophryogenes and 18p deletion: is it possible that the LAMA1 gene is 
          involved? [Brief Report]. J Med Genet 2001;38:127-128.</li>
      </ol>
      <!-- #EndEditable --></td>
  </tr>
  <tr> 
    <td width="44%">&nbsp;</td>
    <td width="19%">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
  </tr>
</table>
</body>
<!-- #EndTemplate --></html>
